Science Sparks @ ACTREC
29 December 2025Publications
- 1. George GS, Patil A, Moirangthem R, Doibale PN, Manjrekar A, Golapkar SV, Panse N, Krishnatreya M, Mishra A, Singh A, Rumgay H, Hosseini B, Chaturvedi A, Rajaraman P, Olsson A, Soerjomataram I, Chaturvedi P, Dikshit R, Mhatre S (2025). Association of alcohol and different types of alcoholic beverages on the risk of buccal mucosa cancer in Indian men: a multicentre case-control study. BMJ Global Health. 10(12):e017392.
- 2. Chopra S, Samanta A, Nagar A, Mittal P, Gupta A, Mulani J, Jain J, Ghadi Y, Sawant P, Rath S, Ghosh J, Gupta S(2025). Is single implant and multiple fractions radio-biologically iso-effective for cervical cancer high-dose-rate brachytherapy: Observation from patient cohorts during COVID pandemic. Brachytherapy.
- 3. Saha A, Pan A, Ghosh D, Pal A, Guin S, Redhu AK, Gota V, Maiti D (2025). A general strategy to access pharmaceutically relevant pyridines from nitroarenes. Angewandte Chemie.
- 4. Le Guevelou J, Zilli T, Ferrario F, Murthy V, Tree A, Loblaw A, Van der Heide UA, Kishan A, Draulans C, Martin J, Ost P, Sargos P (2025). Reducing adverse effects in hypofractionated radiotherapy for prostate cancer: Clinical evidence and emerging mitigation strategies.Prostate Cancer and Prostatic Diseases.
- 5. Gupta R, Fielder T, Bal M..........Chernock R...Kamboj M...Patil A...Rane S...etal. on the behalf of the HN-CLEAR steering committee and clinical advisory group (2026). International consensus recommendations and alignment of terminology for the histopathological diagnosis of extranodal extension in head and neck squamous cell carcinoma: an HN-CLEAR initiative. Lancet Oncology. 27(1):e33-e44.
- 6. Meher RK, Maharana J, Kovvuri J, K. Nirmal Kumar, Pradhan T, Kailaje V, Ingle A, Sen S, Barkume M, Patkar M, Vaibhaw A, Mir SA, Ghosh A, Kamte S, Kamal A, Kode J (2025). A phenstatin-based indole-chalcone hybrid as novel anti-inflammatory agent targeting the NLRP3 Inflammasome: Leads from computational and preclinical studies. Bioorganic Chemistry.
Interesting Reads
Video of the Week
Recognizing and Redefining the Unique Path of Invasive Lobular Carcinoma
Upcoming Events
December 30, 2025
At Khanolkar Auditorium, Khanolkar Shodhika, ACTREC, Kharghar, Navi Mumbai.
January 3, 2026
At Khanolkar Auditorium, Khanolkar Shodhika, ACTREC, Kharghar, Navi Mumbai.
January 15-16, 2026
At ACTREC, Tata Memorial Centre, Kharghar.
Do You Know?
In 1996, FDA approved anastrozole (Arimidex) as a treatment for breast cancer. This drug blocks the production of estrogen.
Cancer News
MedicalXpress, 25/12/2025
In the new study, the researchers used a phage-displayed antibody library, a powerful tool used to discover new antibodies, to create JX1.1, a new antibody that recognizes only the TRBC2 protein target and not the similar TRBC1 protein...
Press Information Bureau, 24/12/2025
A landmark study by Centre for Cancer Epidemiology, The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) at the Tata Memorial Centre, Mumbai, has demonstrated that there is no safe limit for alcohol drinking in the development of oral cancer...
Health Dialogues,22/12/2025
The highlight of this research is its combination of high precision, thermal stability, and long-term drug release (up to 700 hours) — a feat that addresses common drawbacks of existing nanocarrier systems, such as burst release and poor compatibility...
© 2025 Advanced Centre for Treatment, Research and Education in Cancer (ACTREC)